Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
JAMA : the journal of the American Medical Association, 2023-06, Vol.329 (22), p.1934
2023
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection
Ist Teil von
  • JAMA : the journal of the American Medical Association, 2023-06, Vol.329 (22), p.1934
Ort / Verlag
United States
Erscheinungsjahr
2023
Quelle
MEDLINE
Beschreibungen/Notizen
  • SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and infected individuals. To develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections. Prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Selection included population-based, volunteer, and convenience sampling. SARS-CoV-2 infection. PASC and 44 participant-reported symptoms (with severity thresholds). A total of 9764 participants (89% SARS-CoV-2 infected; 71% female; 16% Hispanic/Latino; 15% non-Hispanic Black; median age, 47 years [IQR, 35-60]) met selection criteria. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% [95% CI, 8.8%-11%]) were PASC positive at 6 months. A definition of PASC was developed based on symptoms in a prospective cohort study. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC.
Sprache
Englisch
Identifikatoren
ISSN: 0098-7484
eISSN: 1538-3598
DOI: 10.1001/jama.2023.8823
Titel-ID: cdi_pubmed_primary_37278994

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX